Postbiotics, compositions and applications for synergistically enhancing the hypoglycemic ability of D-psicose

Abstract

The present invention belongs to the technical field of microbial agents, and specifically relates to postbiotics, compositions and applications that synergistically enhance the hypoglycemic ability of D-allulose. Specifically, the present invention combines postbiotics with D-allulose, achieving a significant improvement in the hypoglycemic effect. The present invention uses postbiotics obtained by fermenting Lactobacillus gasseri ( Lactobacillus gasseri ) co-1 in combination with D-allulose, which can more effectively regulate blood glucose metabolism. In addition, the positive effect of postbiotics on intestinal health further enhances the overall hypoglycemic ability. Postbiotics improve the intestinal environment related to metabolic diseases by enhancing the intestinal barrier function and regulating the intestinal flora. This multi-level mechanism of action not only helps to control blood glucose, but also improves the symptoms of pre-diabetes and effectively prevents or delays the development of diabetes, so it has good practical application value.

Description

Technical Field

[0001] The present invention belongs to the technical field of microbial agents, and particularly relates to postbiotics, compositions and applications for synergistically improving the hypoglycemic ability of D-allulose. Background Art

[0002] Diabetes, as a metabolic disease characterized by hyperglycemia, although its pathogenic factors and pathogenesis are complex and variable, controlling the intake of sugars is still one of the most effective means for preventing and treating diabetes. Traditional sweeteners such as sucrose, although able to effectively improve the flavor of food, have the characteristics of high calories and high absorption rate, and can cause various diseases such as obesity, diabetes, and cardiovascular diseases. Using sweeteners with a low blood sugar response to replace sucrose will become an effective method for preventing diseases such as diabetes. D-allulose is an important sweetener raw material and also a commonly used prebiotic. Its energy value is 0.007 kcal / g, and it is called an energy-free sweetener. It can effectively prevent the occurrence of obesity and prevent the increase of blood sugar, and has great application value in the prevention and treatment of metabolic diseases such as diabetes and obesity.

[0003] Postbiotics are collectively referred to as the metabolite components of probiotics after processing, including bacterial cells and metabolites. They have a strong regulatory effect on the intestinal flora. According to clinical observations and research, postbiotics play a role in obesity and diabetes through various mechanisms. These pathways cover increased energy consumption, adipocyte formation and differentiation, and reduced food intake, as well as changes in the absorption and metabolism of lipids and carbohydrates and intestinal flora regulation.

[0004] Prebiotics and postbiotics, as effective means for the intestinal flora and intestinal function, are used in the intervention of blood sugar. Prebiotics can selectively stimulate the growth of beneficial bacteria, while postbiotics can enhance the intestinal barrier function. The two may jointly improve glucose metabolism and insulin sensitivity through different mechanisms. However, there are almost no reports on the synergistic regulation of blood sugar by the prebiotic D-allulose and postbiotics, especially the report on the synergistic improvement of blood sugar in pre-diabetic patients by the two. Summary of the Invention

[0005] Based on the above deficiencies of the prior art, the present invention provides a postbiotic, a composition and an application for synergistically improving the hypoglycemic ability of D-allulose. It has been experimentally proven that the postbiotic prepared from Lactobacillus gasseri based on the present invention can effectively improve the hypoglycemic ability of D-allulose. Combining the two can thus show a more effective blood sugar regulation effect. Based on the above research results, the present invention is completed.

[0006] To achieve the above technical objectives, the present invention relates to the following technical solutions:

[0007] In the first aspect of the present invention, there is provided the use of postbiotics in the preparation of a product for enhancing the hypoglycemic ability of D-allulose;

[0008] wherein the postbiotics comprise inactivated Lactobacillus gasseri ( Lactobacillus gasseri ) co-1;

[0009] The Lactobacillus gasseri ( Lactobacillus gasseri ) co-1 is deposited at the China Center for Type Culture Collection (address: Wuchang Luojia Mountain, Wuhan University, Hubei Province), and the deposit date is January 20, 2025, with the biological deposit number CCTCC NO: M 2025187.

[0010] In the second aspect of the present invention, there is provided a composition comprising postbiotics and D-allulose;

[0011] The mass ratio of the postbiotics to D-allulose is 60 - 100:0.1 - 0.4.

[0012] The postbiotics comprise inactivated Lactobacillus gasseri ( Lactobacillus gasseri ) co-1.

[0013] In the third aspect of the present invention, there is provided a preparation method of the above composition, and the preparation method includes the step of mixing the postbiotics with D-allulose.

[0014] In the fourth aspect of the present invention, there is provided the use of the above composition in the preparation of a product;

[0015] The product has any one or more of the following effects:

[0016] (a) inhibiting the activity of α-glucosidase;

[0017] (b) regulating blood glucose concentration;

[0018] (c) treating or assisting in the treatment of diabetes.

[0019] Through research, the present invention finds that the combination of postbiotics and D-allulose can synergistically inhibit α-glucosidase, and further animal experiments prove that it has the effect of inhibiting blood glucose elevation, thereby playing a role in regulating the blood glucose concentration of diabetic patients.

[0020] In the present invention, the product can be a food, a drug, or a general reagent for non-medical use.

[0021] The beneficial technical effects of the above one or more technical solutions:

[0022] By combining postbiotics with D-allulose, the above technical solution achieves a significant improvement in the hypoglycemic effect. As a calorie-free sweetener, D-allulose itself has the potential to prevent obesity and control blood sugar. However, its effect may be limited when used alone. The above technical solution combines postbiotics obtained by fermenting Lactobacillus gasseri ( Lactobacillus gasseri co-1) with D-allulose to synergistically regulate blood sugar metabolism more effectively. In addition, the positive effect of postbiotics on gut health further enhances the overall hypoglycemic ability. Postbiotics improve the intestinal environment related to metabolic diseases by enhancing the intestinal barrier function and regulating the gut microbiota. This multi-level mechanism of action not only helps control blood sugar but also improves the symptoms of prediabetes and effectively prevents or delays the development of diabetes.

[0023] In summary, through scientific design and optimization, the above technical solution provides a postbiotic and composition that synergistically enhance the hypoglycemic ability of D-allulose, with significant hypoglycemic effects and broad application prospects, offering an innovative solution for the prevention and treatment of diabetes and its pre-stage. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This shows the inhibition rate (A) and IC50 (B) of D-allulose on α-glucosidase in the effect verification of the present invention.

[0025] Figure 2 This shows the inhibition rate (A) and IC50 (B) of postbiotics on α-glucosidase in the effect verification of the present invention.

[0026] Figure 3 This shows the inhibition curve of postbiotics and D-allulose on α-glucosidase in the effect verification of the present invention; where P represents D-allulose; H represents postbiotics; LH represents the combined use of D-allulose and postbiotics.

[0027] Figure 4 This shows the change graph of blood glucose levels of rats in each group in the effect verification of the present invention.

[0028] Figure 5 This shows the change graph of oral glucose tolerance levels of rats in each group in the effect verification of the present invention. DETAILED DESCRIPTION OF THE INVENTION

[0029] It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meaning as commonly understood by those of ordinary skill in the technical field to which the present invention belongs.

[0030] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present invention application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should also be understood that when the terms "comprising" and / or "including" are used in this specification, they indicate the presence of features, steps, operations, devices, components, and / or combinations thereof.

[0031] The present invention will be further explained and illustrated below through examples, but it does not constitute a limitation to the present invention. It should be understood that these examples are only used to illustrate the present invention and not to limit the scope of the present invention.

[0032] It should be noted that the following detailed descriptions are all exemplary and are intended to provide further explanations of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meaning as commonly understood by those of ordinary skill in the technical field to which the present invention belongs.

[0033] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present invention application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should also be understood that when the terms "comprising" and / or "including" are used in this specification, they indicate the presence of features, steps, operations, devices, components, and / or combinations thereof.

[0034] In a typical specific embodiment of the present invention, there is provided an application of postbiotics in the preparation of a product for enhancing the hypoglycemic ability of D-allulose;

[0035] wherein, the postbiotics comprise inactivated Lactobacillus gasseri ( Lactobacillus gasseri ) co-1.

[0036] The Lactobacillus gasseri ( Lactobacillus gasseri ) co-1 is deposited at the China Center for Type Culture Collection (Address: Wuchang Luojiashan, Wuhan University, Hubei Province), the deposit date is January 20, 2025, and its biological deposit number is CCTCC NO: M 2025187, and its 16S rDNA sequence is shown in SEQ ID NO.1.

[0037] Furthermore, the hypoglycemic ability of D-allulose is specifically manifested as inhibiting the activity of α-glucosidase.

[0038] In another specific embodiment of the present invention, there is provided a composition comprising postbiotics and D-allulose;

[0039] The mass ratio of the postbiotics to D-allulose is 60-100:0.1-0.4.

[0040] The postbiotics comprise heat-inactivated Lactobacillus gasseri ( Lactobacillus gasseri ) co-1.

[0041] Furthermore, the postbiotics are prepared by the following method:

[0042] (1) Streak the Lactobacillus gasseri ( Lactobacillus gasseri ) co-1 onto an activation medium to obtain a pure strain;

[0043] (2) Pick a single colony of Lactobacillus gasseri obtained in step (1) and place it in a first culture medium at 35-37 °C for static culture for 14-20 hours to obtain a primary seed solution;

[0044] (3) Inoculate the cultured primary seed solution into a second culture medium, with an inoculation amount of 1-5% (preferably 2%, v / v ) and static culture at 35-37 °C (preferably 37 °C) for 14-20 hours to obtain a secondary seed solution;

[0045] (4) Inoculate the secondary seed solution into a third culture medium, with an inoculation amount of 3-8% (preferably 5%, v / v ) and culture at 35-37 °C (preferably 37 °C), 100-150 r / min (preferably 100 r / min), with the tank pressure maintained at 0.05 MPa for 5-6 hours; then reduce the stirring speed to 50-100 r / min (preferably 80 r / min), lower the fermentation temperature to 35 °C, maintain the tank pressure at 0.05 MPa, adjust the pH to weakly acidic (pH 6.5), and ferment for 3-4 hours; then lower the fermentation temperature to 30 °C, increase the tank pressure to 0.1-0.12 MPa (preferably 0.1 MPa), maintain the pH at weakly acidic (pH 6.5), and continue to ferment for 4-5 hours; then keep the stirring speed and tank pressure unchanged, raise the temperature to 40-50 °C (preferably 45 °C), add glycerol accounting for 0.2-0.5% (preferably 0.3%) of the volume of the fermentation broth to the fermentation broth, and perform high-temperature sterilization.

[0046] Among them, in step (1), the composition of the activation medium is as follows: fructose 1.0-2.0%, yeast peptone 1.0-2.0%, yeast extract powder 0.5-1.0%, beef extract powder 1.0-1.5%, sodium acetate 0.05-0.1%, ammonium citrate 0.05-0.1%, potassium dihydrogen phosphate 0.5-1.0%, agar powder 0.15-0.2%, and adjust the pH to weakly acidic (pH 6.5).

[0047] In step (2), the composition of the first culture medium is as follows: fructose 1.0 - 2.0%, yeast peptone 1.0 - 2.0%, yeast extract powder 0.5 - 1.0%, beef extract powder 1.0 - 1.5%, sodium acetate 0.05 - 0.1%, ammonium citrate 0.05 - 0.1%, potassium dihydrogen phosphate 0.5 - 1.0%, adjust the pH to weakly acidic (pH 6.5).

[0048] In step (3), the composition of the second culture medium is as follows: fructooligosaccharide 1.0 - 1.5%, yam starch 1.0 - 1.5%, fructose 1.0 - 2.0%, yeast peptone 1.0 - 2.0%, yeast extract powder 0.5 - 1.0%, sodium acetate 0.05 - 0.1%, ammonium citrate 0.05 - 0.1%, potassium dihydrogen phosphate 0.5 - 1.0%, adjust the pH to weakly acidic (pH 6.5).

[0049] In step (4), the composition of the third culture medium is as follows: fructooligosaccharide 1.0 - 1.5%, corn starch 1.0 - 1.5%, tyrosine 0.5 - 1%, glucose 1.0 - 2.0%, yeast peptone 1.0 - 2.0%, yeast extract powder 0.5 - 1.0%, sodium acetate 0.05 - 0.1%, ammonium citrate 0.05 - 0.1%, potassium dihydrogen phosphate 0.5 - 1.0%, adjust the pH to weakly acidic (pH 6.5).

[0050] Further, in step (4), the high - temperature sterilization can specifically be carried out by raising the temperature to 85 °C and maintaining it for 30 min for sterilization; furthermore, after high - temperature sterilization of the culture medium, spray - drying is carried out to obtain the post - biogenic powder.

[0051] In another specific embodiment of the present invention, a preparation method of the above - mentioned composition is provided, and the preparation method includes the step of mixing the post - biogen with D - allulose. Further, in a three - dimensional mixer, it is mixed at 80 - 150 r / min (preferably 100 r / min) for 10 - 100 minutes (preferably 60 minutes).

[0052] In another specific embodiment of the present invention, an application of the above - mentioned composition in the preparation of a product is provided;

[0053] The product has any one or more of the following effects:

[0054] (a) Inhibiting the activity of α - glucosidase;

[0055] (b) Regulating blood glucose concentration;

[0056] (c) Treating or assisting in the treatment of diabetes.

[0057] It has been found through research in the present invention that postbiotics combined with D-allulose can synergistically inhibit α-glucosidase, and further animal experiments have proved that it has the effect of inhibiting blood glucose elevation, thereby playing a role in regulating the blood glucose concentration of diabetic groups.

[0058] In the present invention, the product can be a food, a drug or a common reagent for non-medical use.

[0059] The term "food" used in the present invention can be in any edible form, and the food includes ordinary food and special food. The special food includes health food and formula food for special medical purposes; while ordinary food is relative to special food and is food suitable for everyone.

[0060] The drug of the present invention may also contain common carriers, carriers, excipients, diluents, etc. Moreover, according to the usual method, it can be made into dosage forms such as powders, granules, suspensions, emulsions, syrups, sprays, etc., for oral administration, external use, suppositories and sterile injection solutions.

[0061] The present invention is further explained below through examples, but it does not constitute a limitation to the present invention. It should be understood that these examples are only used to illustrate the present invention and not to limit the scope of the present invention. In each example, the specific components of each culture medium are as follows:

[0062] Activated medium: fructose 1.5%, yeast peptone 1.5%, yeast extract powder 1.0%, beef extract powder 1.5%, sodium acetate 0.05%, ammonium citrate 0.05%, potassium dihydrogen phosphate 0.5%, agar powder 0.2%, adjust the pH to 6.5.

[0063] The composition of the first culture solution is as follows: fructose 1.5%, yeast peptone 2.0%, yeast extract powder 0.5, beef extract powder 1.5%, sodium acetate 0.1%, ammonium citrate 0.05%, potassium dihydrogen phosphate 0.5%, adjust the pH to 6.5.

[0064] Second culture solution: fructooligosaccharide 1.5%, yam starch 1.0%, fructose 2.0%, yeast peptone 2.0%, yeast extract powder 1.0%, sodium acetate 0.05%, ammonium citrate 0.05%, potassium dihydrogen phosphate 0.5%, adjust the pH to 6.5.

[0065] Third culture solution: fructooligosaccharide 1.0%, corn starch 1.5%, tyrosine 0.5%, glucose 1.0%, yeast peptone 2.0%, yeast extract powder 0.5%, sodium acetate 0.05, ammonium citrate 0.05%, potassium dihydrogen phosphate 0.5%, adjust the pH to 6.5.

[0066] The “%” of the components in the above activation medium and the first to third culture media is the mass-volume percentage, with the unit of g / mL.

[0067] Example 1

[0068] A method for preparing postbiotics, comprising the following steps:

[0069] Streak Lactobacillus gasseri ( Lactobacillus gasseri ) co-1 onto the activation medium to obtain a pure strain; pick a single colony of the obtained Lactobacillus gasseri and place it in the first culture medium at 37°C for static culture for 20 hours to obtain a primary seed solution; inoculate the primary seed solution into the second culture medium at an inoculation amount of 2% ( v / v ) and statically culture at 37°C for 20 hours to obtain a secondary seed solution.

[0070] Inoculate the above-mentioned Lactobacillus gasseri secondary seed solution into a fermenter containing sterilized third culture medium at an inoculation amount of 5% ( v / v ), at 37°C, 100 r / min, keep the tank pressure at 0.05 MPa, and culture for 6 hours; then reduce the stirring speed to 80 r / min, reduce the fermentation temperature to 35°C, keep the tank pressure at 0.05 MPa, adjust the pH to 6.5 with ammonia water, and ferment for 4 hours; then reduce the fermentation temperature to 30°C, keep the stirring speed unchanged, increase the tank pressure to 0.1 MPa, adjust the pH to 6.5 with ammonia water, and ferment for 5 hours; then keep the stirring speed unchanged, increase the temperature to 45°C, add glycerol at 0.3% of the fermentation broth volume to the fermenter, increase the temperature to 85 °C and keep it for 30 min, and then spray dry.

[0071] Example 2

[0072] Streak Lactobacillus gasseri ( Lactobacillus gasseri ) co-1 onto the activation medium to obtain a pure strain; pick a single colony of the obtained Lactobacillus gasseri and place it in the first culture medium at 37°C for static culture for 20 hours to obtain a primary seed solution; inoculate the primary seed solution into the second culture medium at an inoculation amount of 2% ( v / v ) and statically culture at 37°C for 20 hours to obtain a secondary seed solution.

[0073] Inoculate at an inoculation amount of 5% ( v / vInoculate the above-mentioned secondary seed liquid of Lactobacillus gasseri into a fermenter containing sterilized third culture medium at an inoculum amount of (), culture at 37 °C, 100 r / min, keep the tank pressure at 0.05 MPa for 6 hours; then reduce the stirring speed to 80 r / min, reduce the fermentation temperature to 35 °C, keep the tank pressure at 0.05 MPa, adjust the pH to 6.5 with ammonia water, and ferment for 4 hours; then reduce the fermentation temperature to 30 °C, keep the stirring speed unchanged, increase the tank pressure to 0.1 MPa, adjust the pH to 6.5 with ammonia water, and ferment for 5 hours; then keep the stirring speed unchanged, raise the temperature to 45 °C, add glycerol accounting for 0.3% of the fermentation broth volume to the fermenter, raise the temperature to 85 °C and keep it for 30 min, and then perform spray drying.

[0074] Take 2000 g of the above postbiotics and mix it with 8 g of D-allulose in a three-dimensional mixer at 100 r / min for 60 minutes to obtain a postbiotics D-allulose composition.

[0075] Effect verification

[0076] For the composition for improving hypoglycemic effect, its verification method is as follows:

[0077] Diabetes is a chronic endocrine disorder disease characterized by hyperglycemia. The main way to treat diabetes is to reduce postprandial hyperglycemia. Alpha-glucosidase inhibitors can delay or inhibit the absorption of glucose in the intestine by inhibiting the catalytic degradation of polysaccharides into monosaccharides by alpha-glucosidase in the small intestine, effectively reducing postprandial hyperglycemia. As the first-choice drug for treating type II diabetes, alpha-glucosidase inhibitors have been widely used clinically. Therefore, when evaluating the hypoglycemic effect of a certain component, it is usually evaluated by its inhibitory effect on alpha-glucosidase. In the present invention, p-nitrophenyl alpha-D-glucoside (alpha-PNPG) is used as a substrate, and this substrate is hydrolyzed to generate p-nitrophenol (PNP) under the action of alpha-glucosidase, and PNP has a specific absorption peak at 405 nm. Based on this principle, we evaluated the inhibitory effect of the test sample on the activity of alpha-glucosidase. The specific measurement process is as follows, and the specific reagent addition volumes are shown in Table 1.

[0078] Absorb 200 μL of sample solutions with different concentrations and 200 μL of α-glucosidase solution (1.5 U / mL). After mixing evenly, incubate in a water bath at 37 °C for 5 minutes. Add 200 μL of PNPG solution (2.5 mmol / L), mix evenly, and continue to incubate in a water bath at 37 °C for 15 minutes. Add 800 μL of Na2CO3 solution (0.2 mol / L) to terminate the reaction and stop the hydrolysis reaction of α-glucosidase. According to the specific absorption principle of p-nitrophenol (PNP) at 405 nm, absorb 160 μL of the reaction termination solution into a 96-well plate and measure the absorbance (OD value) at a wavelength of 405 nm in an enzyme-linked immunosorbent assay (ELISA) reader. By detecting the production amount of PNP generated by the hydrolysis of α-PNPG by α-glucosidase after adding D-allulose and postbiotics, calculate the inhibition rate to evaluate the effect of D-allulose and postbiotics on the activity of α-glucosidase. Each sample is measured in parallel 3 times, and the average value is taken to improve the accuracy and reliability of the data.

[0079]

[0080] Table 1 Configuration of the α-glucosidase inhibition rate system

[0081]

[0082] (1) According to the above method for measuring the inhibitory activity of α-glucosidase, measure the effect of D-allulose on the activity of α-glucosidase at concentrations of 10, 50, 100, 200, 300, and 500 μg / mL, respectively. The results are as shown in Figure 1 A below. It can be seen that the inhibitory effect of D-allulose on α-glucosidase increases with the increase in concentration. Take the logarithm of the D-allulose concentration (X) and establish a linear regression equation with the inhibition rate (Y) to calculate the IC50 value. As shown in Figure 1 B below, the IC50 value of D-allulose for α-glucosidase is 286.1 μg / mL.

[0083] (2) Similarly, according to the above method for measuring the inhibitory activity of α-glucosidase, measure the effect of postbiotics on the activity of α-glucosidase at concentrations of 20, 40, 60, 80, 150, and 200 mg / mL, respectively. The results are as shown in Figure 2 A below. It can be seen that the inhibitory effect of postbiotics on α-glucosidase increases with the increase in concentration. Take the logarithm of the postbiotic addition concentration (X) and establish a linear regression equation with the inhibition rate (Y) to calculate the IC50 value. As shown in Figure 2 B below, the IC50 value of postbiotics for α-glucosidase is 74.38 mg / mL.

[0084] (3)According to the above method, the inhibitory activity of postbiotics and D-allulose on α-glucosidase was measured. When postbiotics and D-allulose were used in combination, the final concentrations of D-allulose were 100, 200, and 400 μg / mL, respectively, and the final concentrations of postbiotics were 60, 80, and 100 mg / mL, respectively. Different concentration combinations of postbiotics and D-allulose were set, with a total of 9 groups. According to the aforementioned method, the effects of different concentration combinations of postbiotics and D-allulose on α-glucosidase activity were measured. The combination index (CI) was calculated using the Chou-Talalay method to evaluate the interaction relationship between postbiotics and D-allulose. The CI values of the inhibitory effects of postbiotics and D-allulose on α-glucosidase were calculated by CompuSyn 1.0 software. Among them, CI < 1 indicates a synergistic effect between postbiotics and D-allulose, CI = 1 indicates an additive effect between postbiotics and D-allulose, and CI > 1 indicates an antagonistic effect between postbiotics and D-allulose. The results are shown in Table 2, and the Fa graph obtained by the software CompuSyn 1.0 is as Figure 3 shown. It can be seen from the results that the CI values of different concentration combinations of postbiotics and D-allulose are all less than 1, indicating that there is a synergistic effect between postbiotics and D-allulose on the inhibition of α-glucosidase.

[0085] Table 2 Inhibitory effect of combined use of D-allulose and postbiotics on α-glucosidase activity

[0086]

[0087] The method for verifying the effect of the said composition on regulating blood glucose in diabetic rats is as follows:

[0088] SD rats with an initial body weight of 180 - 200 g were selected and adaptively fed for 1 week. After normal blood glucose detection, 6 rats were screened out as the normal control group, and the other rats were fasted but not water-deprived for 24 hours and then modeled. The animals in the modeling group were injected with STZ at 39 mg / kg via the tail vein, and the control group was given an equal volume of citrate buffer solution. After 72 hours, blood glucose and urine glucose were measured, and animals with a blood glucose concentration > 16.7 mmol / L were regarded as successfully modeled. The diabetic rats were randomly divided into 5 groups by random sampling method. The model group (equal volume of normal saline), Example 1 group (100 mg / kg), and Example 2 group (100 mg / kg), with 6 rats in each group, were given intragastric administration once a day for 6 consecutive weeks. During the feeding process, the tail blood of the rats was collected weekly to measure the fasting blood glucose (FBG) level. After five weeks of feeding, the oral glucose tolerance of the rats was measured.

[0089] As expected, compared with the control Wistar rats, the FBG levels of the rats in Example 1 and Example 2 groups decreased at all time points, and the decrease in the Example 2 group was significant ( Figure 4 ). Further detection of oral glucose tolerance showed that the glucose concentration increments in the Example 1 and Example 2 groups at 2 hours and 3 hours were significantly lower than those in the model group, especially in the Example 2 group ( Figure 5 ).

[0090] Nucleotide sequence information involved in this application:

[0091] Lactobacillus gasseri ( Lactobacillus gasseri ) co-1 16S rDNA sequence:

[0092]

[0093] The above embodiments are only used to illustrate the technical concept and features of the present invention. The purpose is to enable those skilled in the art to understand the content of the present invention and implement it accordingly, and it cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be covered within the protection scope of the present invention.

Claims

1. A composition, characterized in that, The composition is postbiotics and D-allulose; the mass ratio of the postbiotics to D-allulose is 60 - 100:0.1 - 0.4; The postbiotics are prepared by the following method: (1) Streak Lactobacillus gasseri ( lactobacillus gasseri ) co-1 onto an activation medium to obtain a pure strain; (2) Pick a single colony of Lactobacillus gasseri obtained in step (1) and place it in the first culture medium at 35 - 37 °C for static culture for 14 - 20 hours to obtain a primary seed solution; (3) Inoculate the cultured primary seed solution into the second culture medium, with an inoculation amount of 1 - 5%, and perform static culture at 35 - 37 °C for 14 - 20 hours to obtain a secondary seed solution; (4) Inoculate the secondary seed solution into the third culture medium, with an inoculation amount of 3 - 8%, at 35 - 37 °C, 100 - 150 r / min, and keep the tank pressure at 0.05 MPa for 5 - 6 hours; then reduce the stirring speed to 50 - 100 r / min, lower the fermentation temperature to 35 °C, keep the tank pressure at 0.05 MPa, adjust the pH to weakly acidic, and ferment for 3 - 4 hours; then lower the fermentation temperature to 30 °C, increase the tank pressure to 0.1 - 0.12 MPa, maintain the pH at weakly acidic, and continue to ferment for 4 - 5 hours; then keep the stirring speed and tank pressure unchanged, raise the temperature to 40 - 50 °C, add glycerol accounting for 0.2 - 0.5% of the volume of the fermentation broth to the fermentation broth, and perform high-temperature sterilization; The Lactobacillus gasseri ( lactobacillus gasseri ) co-1, which was deposited at the China Center for Type Culture Collection on January 20, 2025, and its biological deposit number is CCTCC NO: M 2025187.

2. The composition according to claim 1, characterized in that, In step (1), the composition of the activation medium is as follows: D-allulose 1.0% - 2.0%, yeast peptone 1.0% - 2.0%, yeast extract powder 0.5% - 1.0%, beef extract powder 1.0% - 1.5%, sodium acetate 0.05 - 0.1%, ammonium citrate 0.05 - 0.1%, potassium dihydrogen phosphate 0.5 - 1.0%, agar powder 0.15 - 0.2%, and adjust the pH to weakly acidic; In step (2), the composition of the first culture medium is as follows: D-allulose 1.0% - 2.0%, yeast peptone 1.0% - 2.0%, yeast extract powder 0.5% - 1.0%, beef extract powder 1.0% - 1.5%, sodium acetate 0.05 - 0.1%, ammonium citrate 0.05 - 0.1%, potassium dihydrogen phosphate 0.5 - 1.0%, and adjust the pH to weakly acidic; In step (3), the composition of the second culture medium is as follows: fructooligosaccharide 1.0 - 1.5%, yam starch 1.0 - 1.5%, fructose 1.0 - 2.0%, yeast peptone 1.0 - 2.0%, yeast extract powder 0.5 - 1.0%, sodium acetate 0.05 - 0.1%, ammonium citrate 0.05 - 0.1%, potassium dihydrogen phosphate 0.5 - 1.0%, and adjust the pH to weakly acidic; In the step (4), the composition of the third culture medium is as follows: fructooligosaccharide 1.0 - 1.5%, corn starch 1.0 - 1.5%, tyrosine 0.5 - 1%, glucose 1.0 - 2.0%, yeast peptone 1.0 - 2.0%, yeast extract powder 0.5 - 1.0%, sodium acetate 0.05 - 0.1%, ammonium citrate tribasic 0.05 - 0.1%, potassium dihydrogen phosphate 0.5 - 1.0%, and the pH is adjusted to weakly acidic.

3. The composition according to claim 1, characterized in that, In the step (4), the high-temperature sterilization is specifically carried out by raising the temperature to 85 °C and maintaining it for 30 min for sterilization.

4. The composition according to claim 1, wherein In the step (4), the culture medium after high-temperature sterilization is spray-dried to obtain the postbiotic powder.

5. The preparation method of the composition according to any one of claims 1-4, characterized in that, The preparation method includes the step of mixing the postbiotic with D-allulose.

6. Use of the composition according to any one of claims 1 - 4 in the preparation of a medicament for treating diabetes.

7. Use of the composition according to any one of claims 1 - 4 in the preparation of a medicament for adjuvant treatment of diabetes.

Images